{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T22:39:24Z","timestamp":1776379164784,"version":"3.51.2"},"reference-count":64,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Initial clinical trials and surveillance data have shown that the most commonly administered BNT162b2 COVID-19 mRNA vaccine is effective and safe. However, several cases of mRNA vaccine-induced mild to moderate adverse events were recently reported. Here, we report a rare case of myositis after injection of the first dose of BNT162b2 COVID-19 mRNA vaccine into the left deltoid muscle of a 34-year-old, previously healthy woman who presented progressive proximal muscle weakness, progressive dysphagia, and dyspnea with respiratory failure. One month after vaccination, BNT162b2 vaccine mRNA expression was detected in a tissue biopsy of the right deltoid and quadriceps muscles. We propose this case as a rare example of COVID-19 mRNA vaccine-induced myositis. This study comprehensively characterizes the clinical and molecular features of BNT162b2 mRNA vaccine-associated myositis in which the patient was severely affected.<\/jats:p>","DOI":"10.3390\/vaccines10071135","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T01:53:22Z","timestamp":1658109202000},"page":"1135","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7713-423X","authenticated-orcid":false,"given":"Eli","family":"Magen","sequence":"first","affiliation":[{"name":"Medicine C Department, Clinical Immunology and Allergy Division, Barzilai University Medical Center, Ben-Gurion University of the Negev, Ashkelon 7830604, Israel"},{"name":"Leumit Health Services, Tel Aviv 6473817, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9807-7994","authenticated-orcid":false,"given":"Sumit","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel"},{"name":"Department of Computer Science, Ben-Gurion University, Beer-Sheva 8410501, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5114-5678","authenticated-orcid":false,"given":"Mahua","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-6998","authenticated-orcid":false,"given":"Rajesh","family":"Detroja","sequence":"additional","affiliation":[{"name":"Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Merzon","sequence":"additional","affiliation":[{"name":"Leumit Health Services, Tel Aviv 6473817, Israel"},{"name":"Department of Family Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idan","family":"Blum","sequence":"additional","affiliation":[{"name":"Medicine C Department, Clinical Immunology and Allergy Division, Barzilai University Medical Center, Ben-Gurion University of the Negev, Ashkelon 7830604, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Livoff","sequence":"additional","affiliation":[{"name":"Pathology Department, Barzilai University Medical Center, Ashkelon 7830604, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4819-935X","authenticated-orcid":false,"given":"Mark","family":"Shlapobersky","sequence":"additional","affiliation":[{"name":"Pathology Department, Barzilai University Medical Center, Ashkelon 7830604, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon","family":"Baum","sequence":"additional","affiliation":[{"name":"Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Talisman","sequence":"additional","affiliation":[{"name":"Plastic Surgery Department, Barzilai University Medical Center, Ashkelon 7830604, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgenia","family":"Cherniavsky","sequence":"additional","affiliation":[{"name":"Imaging Department, Barzilai University Medical Center, Ashkelon 7830604, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-1481","authenticated-orcid":false,"given":"Amir","family":"Dori","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sheba Medical Center, Ramat Gan 5262000, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0329-4599","authenticated-orcid":false,"given":"Milana","family":"Frenkel-Morgenstern","sequence":"additional","affiliation":[{"name":"Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"m4799","DOI":"10.1136\/bmj.m4799","article-title":"COVID-19: FDA panel votes to approve Pfizer BioNTech vaccine","volume":"371","author":"Tanne","year":"2020","journal-title":"BMJ"},{"key":"ref_2","unstructured":"Haas, E.J., Angulo, F.J., McLaughlin, J.M., Anis, E., Singer, S.R., Khan, F., Brooks, N., Smaja, M., Mircus, G., and Pan, K. (2022, June 17). Nationwide Vaccination Campaign with BNT162b2 in Israel Demonstrates High Vaccine Effectiveness and Marked Declines in Incidence of SARS-CoV-2 Infections and COVID-19 Cases, Hospitalizations, and Deaths. SSRN, Available online: https:\/\/ssrn.com\/abstract=3811387."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"JC15","DOI":"10.7326\/ACPJ202102160-015","article-title":"The BNT162b2 (BioNTech\/Pfizer) vaccine had 95% efficacy against COVID-19 \u2265 7 days after the 2nd dose","volume":"174","author":"Chagla","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jiac.2021.12.034","article-title":"Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan","volume":"28","author":"Kitagawa","year":"2022","journal-title":"J. Infect. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1080\/21645515.2021.1989923","article-title":"COVID-19 vaccine hesitancy among youth","volume":"17","author":"Willis","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102830","DOI":"10.1016\/j.jaut.2022.102830","article-title":"Autoimmune conditions following mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccination: A descriptive cohort study among 1.1 million vaccinated people in Hong Kong","volume":"130","author":"Li","year":"2022","journal-title":"J. Autoimmun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"107970","DOI":"10.1016\/j.intimp.2021.107970","article-title":"Autoimmune phenomena following SARS-CoV-2 vaccination","volume":"99","author":"Ishay","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00296-021-04792-9","article-title":"SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis","volume":"41","author":"Velikova","year":"2021","journal-title":"Rheumatol. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Furer, V., Eviatar, T., Zisman, D., Peleg, H., Braun-Moscovici, Y., Balbir-Gurman, A., Paran, D., Levartovsky, D., Zisapel, M., and Elalouf, O. (2022). Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab. Vaccines, 10.","DOI":"10.3390\/vaccines10060901"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clicom.2021.12.002","article-title":"Guillain-Barre syndrome: An autoimmune disorder post-COVID-19 vaccination?","volume":"2","author":"Khan","year":"2022","journal-title":"Clin. Immunol. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1007\/s10072-021-05523-5","article-title":"Guillain-Barr\u00e9 syndrome following BNT162b2 COVID-19 vaccine","volume":"42","author":"Trimboli","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/qjmed\/hcac102","article-title":"Guillain\u2013Barr\u00e9 syndrome after BNT162b2 (Pfizer-BioNTec) vaccination","volume":"115","author":"Takahashi","year":"2022","journal-title":"QJM Int. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamaneurol.2021.3287","article-title":"Rate of Recurrent Guillain-Barr\u00e9 Syndrome After mRNA COVID-19 Vaccine BNT162b2","volume":"78","author":"Potasman","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s10072-021-05849-0","article-title":"Guillain\u2013Barr\u00e9 syndrome associated with BNT162b2 COVID vaccination: A first case report from South Korea","volume":"43","author":"Kim","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"120102","DOI":"10.1016\/j.jns.2021.120102","article-title":"Acute transverse myelitis after BNT162b2 vaccination against COVID-19: Report of a fatal case and review of the literature","volume":"434","author":"Nakano","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"215013272110519","DOI":"10.1177\/21501327211051933","article-title":"A Case of COVID-19 Vaccine Associated New Diagnosis Myasthenia Gravis","volume":"12","author":"Chavez","year":"2021","journal-title":"J. Prim. Care Community Health"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"120225","DOI":"10.1016\/j.jns.2022.120225","article-title":"Flare of myasthenia gravis induced by COVID-19 vaccines","volume":"436","author":"Ishizuchi","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1007\/s00415-022-11140-9","article-title":"Vaccines and myasthenia gravis: A comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients","volume":"269","author":"Sansone","year":"2022","journal-title":"J. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/neurolint14020033","article-title":"Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort","volume":"14","author":"Lupica","year":"2022","journal-title":"Neurol. Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.nmd.2022.01.013","article-title":"Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis","volume":"32","author":"Lotan","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40629-020-00160-4","article-title":"Severe allergic reactions after COVID-19 vaccination with the Pfizer\/BioNTech vaccine in Great Britain and USA","volume":"30","author":"Klimek","year":"2021","journal-title":"Allergo J. Int."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Lim, X.R., Leung, B.P., Ng, C.Y.L., Tan, J.W.L., Chan, G.Y.L., Loh, C.M., Tan, G.L.X., Goh, V.H.H., Wong, L.T., and Chua, C.R. (2021). Pseudo-anaphylactic reactions to pfizer bnt162b2 vaccine: Report of 3 cases of anaphylaxis post pfizer bnt162b2 vaccination. Vaccines, 9.","DOI":"10.3390\/vaccines9090974"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"taab090","DOI":"10.1093\/jtm\/taab090","article-title":"High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: A secondary analysis of initial post-approval safety data","volume":"28","author":"Hashimoto","year":"2021","journal-title":"J. Travel Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e2122255","DOI":"10.1001\/jamanetworkopen.2021.22255","article-title":"Prevalence of Allergic Reactions after Pfizer-BioNTech COVID-19 Vaccination among Adults with High Allergy Risk","volume":"4","author":"Shavit","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ajh.26132","article-title":"Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination","volume":"96","author":"Lee","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e01245","DOI":"10.1016\/j.idcr.2021.e01245","article-title":"Immune thrombocytopenia associated with Pfizer-BioNTech\u2019s BNT162b2 mRNA COVID-19 vaccine","volume":"25","author":"Akiyama","year":"2021","journal-title":"IDCases"},{"key":"ref_30","first-page":"e18985","article-title":"A Case of Idiopathic Thrombocytopenic Purpura After Booster Dose of BNT162b2 (Pfizer-Biontech) COVID-19 Vaccine","volume":"13","author":"Malayala","year":"2021","journal-title":"Cureus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"751598","DOI":"10.3389\/fmed.2021.751598","article-title":"Potential Triggers for Thrombocytopenia and\/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech","volume":"8","author":"Okada","year":"2021","journal-title":"Front. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1016\/j.vaccine.2021.05.087","article-title":"Myocarditis following COVID-19 mRNA vaccination","volume":"39","author":"Roguin","year":"2021","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA Vaccine against COVID-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1001\/jama.2022.4425","article-title":"Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel","volume":"327","author":"Friedensohn","year":"2022","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Liuzzo, G., and Volpe, M. (2022). Myocarditis after BNT162b2 mRNA SARS-CoV-2 vaccine: Low incidence and mild severity. Eur. Heart J.","DOI":"10.1093\/eurheartj\/ehab901"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.recesp.2022.01.004","article-title":"Acute myocarditis after a third dose of the BNT162b2 COVID-19 vaccine","volume":"75","author":"Fosch","year":"2022","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/qjmed\/hcab043","article-title":"COVID-19 vaccine-related myositis","volume":"114","author":"Theodorou","year":"2021","journal-title":"QJM Int. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13256-022-03266-1","article-title":"Inflammatory myopathy occurring shortly after severe acute respiratory syndrome coronavirus 2 vaccination: Two case reports","volume":"16","author":"Vutipongsatorn","year":"2022","journal-title":"J. Med. Case Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.3346\/jkms.2022.37.e91","article-title":"Clinicopathological Characteristics of Inflammatory Myositis Induced by COVID-19 Vaccine (Pfizer-BioNTech BNT162b2): A Case Report","volume":"37","author":"Kim","year":"2022","journal-title":"J. Korean Med. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3949\/ccjm.88a.21038","article-title":"COVID-19 vaccine-induced cellulitis and myositis","volume":"88","author":"Ramalingam","year":"2021","journal-title":"Cleve. Clin. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.3346\/jkms.2022.37.e32","article-title":"Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination","volume":"37","author":"Gouda","year":"2022","journal-title":"J. Korean Med. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"762006","DOI":"10.3389\/fimmu.2021.762006","article-title":"Case Report: ANCA-Associated Vasculitis Presenting with Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination","volume":"12","author":"Hakroush","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102170","DOI":"10.1016\/j.dsx.2021.06.007","article-title":"COVID-19 vaccine induced rhabdomyolysis: Case report with literature review","volume":"15","author":"Nassar","year":"2021","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Kimura, M., Niwa, J.-I., and Doyu, M. (2022). Recurring Weakness in Rhabdomyolysis Following Pfizer\u2013BioNTech Coronavirus Disease 2019 mRNA Vaccination. Vaccines, 10.","DOI":"10.3390\/vaccines10060935"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie2","volume":"9","author":"Langmead","year":"2013","journal-title":"Nat. Methods"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/bib\/bbs017","article-title":"Integrative Genomics Viewer (IGV): High-performance genomics data visualization and exploration","volume":"14","author":"Robinson","year":"2013","journal-title":"Brief. Bioinform."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1261\/rna.045104.114","article-title":"Determination of in vivo RNA kinetics using RATE-seq","volume":"20","author":"Neymotin","year":"2014","journal-title":"RNA"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Xia, X. (2021). Detailed dissection and critical evaluation of the pfizer\/biontech and moderna mrna vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9070734"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles\u2014From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e32536","DOI":"10.7554\/eLife.32536","article-title":"Non-invasive measurement of mRNA decay reveals translation initiation as the major determinant of mRNA stability","volume":"7","author":"Chan","year":"2018","journal-title":"eLife"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"E57","DOI":"10.1002\/mus.27003","article-title":"COVID-19\u2013associated myositis with severe proximal and bulbar weakness","volume":"62","author":"Zhang","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11926-021-01023-9","article-title":"COVID-19 and Myositis: What We Know So Far","volume":"23","author":"Saud","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Setting","volume":"385","author":"Barda","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijbiomac.2022.01.118","article-title":"Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic","volume":"204","author":"Nayel","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/d41586-022-01771-3","article-title":"Fast-evolving COVID variants complicate vaccine updates","volume":"607","author":"Callaway","year":"2022","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"27456","DOI":"10.1073\/pnas.2008590117","article-title":"Seasonality and uncertainty in global COVID-19 growth rates","volume":"117","author":"Merow","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/2211-5463.13309","article-title":"Seasonal UV exposure and vitamin D: Association with the dynamics of COVID-19 transmission in Europe","volume":"12","author":"Mukherjee","year":"2022","journal-title":"FEBS Open Bio"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"101403","DOI":"10.1016\/j.nantod.2022.101403","article-title":"Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting","volume":"43","author":"Papi","year":"2022","journal-title":"Nano Today"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Mukherjee, S., Tworowski, D., Detroja, R., Mukherjee, S.B., and Frenkel-Morgenstern, M. (2020). Immunoinformatics and structural analysis for identification of immunodominant epitopes in SARS-CoV-2 as potential vaccine targets. Vaccines, 8.","DOI":"10.3390\/vaccines8020290"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"D1113","DOI":"10.1093\/nar\/gkaa969","article-title":"COVID19 Drug Repository: Text-mining the literature in search of putative COVID19 therapeutics","volume":"49","author":"Tworowski","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41586-021-04232-5","article-title":"A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity","volume":"601","author":"Heitmann","year":"2022","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Cohen, A.A., van Doremalen, N., Greaney, A.J., Andersen, H., Sharma, A., Starr, T.N., Keeffe, J.R., Fan, C., Schulz, J.E., and Gnanapragasam, P.N.P. (2022). Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science.","DOI":"10.1126\/science.abq0839"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/7\/1135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:52:11Z","timestamp":1760140331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/7\/1135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,16]]},"references-count":64,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["vaccines10071135"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10071135","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,16]]}}}